Ironwood Pharmaceuticals (IRWD) Non-Current Deffered Revenue (2010 - 2018)

Ironwood Pharmaceuticals (IRWD) has 9 years of Non-Current Deffered Revenue data on file, last reported at $6.3 million in Q4 2018.

• For the quarter ending Q4 2018, Non-Current Deffered Revenue rose 15.76% year-over-year to $6.3 million; the trailing twelve-month figure through Dec 2018 stood at $6.3 million (up 15.76% YoY), and the FY2018 full-year result was $6.3 million, up 15.76% from the prior year.
• Non-Current Deffered Revenue rose to $6.3 million in Q4 2018, from $6.1 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $10.5 million in Q4 2014 to a low of $557000.0 in Q4 2016.
• A 5-year average of $6.1 million and a median of $6.1 million in 2018 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue sank 91.29% in 2016 and jumped 878.28% in 2017, its largest moves.
• Tracing IRWD's Non-Current Deffered Revenue over 5 years: stood at $10.5 million in 2014, then tumbled by 39.22% to $6.4 million in 2015, then slumped by 91.29% to $557000.0 in 2016, then jumped by 878.28% to $5.4 million in 2017, then advanced by 15.76% to $6.3 million in 2018.
• Business Quant data shows IRWD's Non-Current Deffered Revenue at $6.3 million in Q4 2018, $6.1 million in Q3 2018, and $6.1 million in Q2 2018.